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0022-0736/© 2019 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oKeywords: Introduction: Remote monitoring including transmission of electrocardiogram (ECG) strips has been imple-
mented in implantable cardiacmonitors (ICM). We appraise whether the physician can rely on remote monitor-
ing to be informed of all possibly significant arrhythmias.
Methods: We analyzed remote monitoring transmissions of patients in the ongoing BIO|GUARD-MI study, in
which Biotronik devices are used. Once per day, the devices automatically transmit messages with up to six
ECG snapshots to the Home Monitoring Service Center. If more than one type of arrhythmia is recorded during
a day, at least one ECG of each arrhythmia type is transmitted.
Results: 212 study patients were registered at the service center. The mean age of the patients was 70± 8 years,
and 74% were male. Patients were followed for an average of 13 months. The median time from device implan-
tation until thefirstmessage receipt in the service centerwas 2 days. Themedian patient-individual transmission
success was 98.0% (IQR 93.6–99.8) and remained stable in the second and third year. Themost frequent arrhyth-
mias were atrial fibrillation, bradycardia and high ventricular rate. 17.3% of the messages with ECG snapshots
contained more than one arrhythmia type.
Discussion: Our analysis confirms that the physician can rely on Home Monitoring to be informed of all possibly
significant arrhythmias during long-term follow-up. We have found hints that the transmission of only one ep-
isode per daymay lead to the loss of clinically relevant information if patients with ICMs are followed by remote
monitoring only.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Arrhythmia detection
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Implantable cardiac monitors (ICMs) are used to detect cardiac
rhythm disturbances that are too rare to be captured by conventional
24- or 48-hour Holter electrocardiogram (ECG) [1]. The role of ICMs is
established for the clarification of unexplained symptoms [2,3] and
ICMs have been shown to be effective in identifying atrial fibrillation
(AF) in patients with stroke of unclear origin [4]. Beyond these indica-
tions, ICMs are discussed for new fields such as guidingmedical therapy
for AF and risk stratification in structural heart disease [1,5,6]. Remote
monitoring including transmission of ECG strips has relieved thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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allows patient surveillance without regular in-hospital visits [1].
However, a strategy of remote follow-up depends on reliable and
complete remotemonitoring transmission from ICMs is over longer pe-
riods of monitoring. Furthermore, the number of transmitted ECG strips
per day is limited by technological constraints, and evidence on relevant
rhythm disturbances may therefore be supplanted by less relevant epi-
sodes, such as nightly bradycardia, recurrent AF episodes in patients
with known AF, or inappropriate detections. In some persons, the
truly relevant arrhythmias may be rare in comparison to the episodes
of known arrhythmias or incorrect detections, potentially leading to
the loss of relevant events which were detected by the ICM but not
transmitted by remote monitoring.
The novel ICMmodel BioMonitor III and its predecessor BioMonitor
2 use the established Home Monitoring system (Biotronik SE & Co. KG;
Berlin, Germany) [7–9]. They transmit a daily message thatmay contain
up to six ECG snapshots. In the present subanalysis of the BIO|GUARD-
MI study, we evaluate the remote monitoring transmission success
rate during long-term follow-up and the availability of ECG strips. The
goal of the subanalysis is to appraise to which extent the physician
can rely on remote monitoring to be informed of all possibly significant
arrhythmias.
Material and methods
BIO|GUARD-MI study design
The completed Cardiac Arrhythmias and Risk Stratification After
Myocardial Infarction (CARISMA) study has shown that patients who
present with arrhythmias after myocardial infarction (MI) have an in-
creased risk of major adverse cardiac events [5]. However, the study
was not able to show that intervention after arrhythmias would im-
prove the outcome. The ongoing BIO|GUARD-MI study is designed to
answer this question. It investigates whether the incidence of major ad-
verse cardiac events in patients after MI can be decreased by early de-
tection of cardiac arrhythmias using an ICM, and by the subsequent
treatment of the underlying medical cause. A publication of the study
rationale and design is under review. Briefly, patients older than
18 years are included in BIO|GUARD-MI after acute or chronic MI if
they have a left ventricular ejection fraction N35%, no other cardiovascu-
lar implantable electronic device, no permanent anticoagulation treat-
ment for atrial fibrillation (AF) and a CHA2DS2-VASc-Score ≥4 (men)
or ≥5 (women). The CHA2DS2-VASc-Score has been developed the
quantify the stroke risk in AF patients but has also been shown valuable
as a general cardiovascular risk score. All enrolled patients have given
written informed consent before enrollment, which comprises the sci-
entific analysis of remote monitoring data. Appropriate national and
local ethics committees approved the study protocol which is per-
formed in compliance with good clinical practice guidelines and the
Declaration of Helsinki (ClinicalTrials.gov Identifier: NCT02341534).
Patients are randomized in a 1:1 matrix to standard post-MI treat-
ment with or without ICM insertion. An estimated 1500 patients will
be enrolled and followed until 372 primary endpoints have occurred.
After randomization, patients are not scheduled to return to the
implanting hospital but may be invited for further check-up if an ar-
rhythmia is detected. The retrieval of the information from ICMs is
thus completely dependent on a functioning remote monitoring
transmission.
Features of the implantable cardiac monitor
The BioMonitor 2 or successor Biotronik ICM devices are used in the
study [7,8]. After its subcutaneous insertion, the ICM continuouslymon-
itors the heart rhythm to detect and store episodes of AF (based on
rhythm irregularity), bradycardia and high ventricular rate (HVR; both
based on heart rate and minimum duration), asystole (based on pauselength) and sudden rate drop (SRD; based on the heart rate drop in per-
cent). The device automatically records a subcutaneous ECG (sECG)
triggered by programmed criteria. Further, sECGs can be stored at pre-
defined regular intervals (scheduledperiodic recording) or aftermanual
trigger by the patient.
The ICMautomatically transmits amessage once per day, typically in
the early morning hours [9]. The message can contain up to six uncom-
pressed full-length sECG snapshots. An example sECG is shown in Fig. 1.
The most recent recordings are preferentially sent. If more than one
type of arrhythmia is recorded during a day, episodes will be transmit-
ted according to the following ranking: patient-triggered recording,
asystole, HVR, bradycardia, SRD, AF. This approach ensures that at
least one episode of each trigger type is transmitted. The global Home
Monitoring Service Center (HMSC) receives the transmitted data using
Biotronik Home Monitoring® (HM) technology [9]. The physician can
assess the message content on a secure website.
Present analysis
We retrieved from the HMSC all HM transmissions of all patients en-
rolled in the BIO|GUARD-MI study by Jan 30, 2019. To confine the anal-
ysis to spontaneous arrhythmias, we excluded patient-triggered and
periodic sECG snapshots. Days with a message are defined as days on
which a message is received in the HMSC until 9:00 A.M. next day.
This decision was made under the assumption that a clinic typically
checks new HM messages at the beginning of a working day. Gross
overall transmission rate was calculated as the number of days with a
HM message divided by the number of patient-days between the first
and the last transmission. We also calculated the transmission rate for
all patients individually.
Metric data are reported as mean ± standard deviation (SD) or as
median and interquartile range (IQR). Categorical data are shown as ab-
solute and relative frequencies. The analysis was conducted with the R
3.3 statistical software (R Development Core Team, Vienna, Austria).
Results
Patients
On 30 Jan 2019, 212 patients had been registered at the HMSC as
participants of the BIO|GUARDMI study. All patients received a BioMon-
itor 2 ICM device. The mean age of the patients was 70 ± 8 years, and
74% were male. The CHA2DS2-VASc-Score was mostly 4 (44%), 5
(37%), or 6 (16%). The prevalence of hypertension was 95%, diabetes
58%, renal disease 10%, and congestive heart failure 39%. In patients
with heart failure, the New York Heart Association symptom class was
I (45%), II (51%), or III (5%).
Home Monitoring transmission
The median time from device insertion until the first HM message
was received in the HMSC was 2 days (IQR 2–4.5; mean ± SD, 5.2 ±
10.1). Thereafter, the total observation period until the last message in
each patient was 87,252 patient-days (on average, 13 months per pa-
tient). During this period, HMmessages were received on 80,404 days,
yielding a gross overall transmission rate of 92.2%. The patient-
individual transmission success was 93.4 ± 12.1% (median 98.0, IQR
93.6–99.8), with a negligible decline over 3 years of follow-up (Table 1).
ECG transmission and content
The percentage of HMmessages with sECG strips was 27.6% (22,158
out of 80,404messages, excluding patient-triggered and periodic sECG).
The 22,158 HMmessages contained a total of 78,541 sECG strips (3.5 ±
2.2 per message). As many as 8391 messages (37.9% of messages with
Fig. 1. Example sECG strip. The signal from 50 to 14 s before the asystole was detected is cut for clarity. The patient was diagnosed as a third degree AV block and received a pacemaker.
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Table 1
Stability of patient-individual HM transmission success rates over time.
Time period Patient-individual transmission success rate
Mean ± SD Median (IQR) N=
During the 1st year of FU (%) 94.2 ± 10.8 98.4 (94.0–100) 212
During the 2nd year of FU (%) 90.3 ± 18.3 97.7 (89.6–100) 113
During the 3rd year of FU (%) 93.8 ± 11.7 97.1 (93.5–100) 37
Total (%) 93.4 ± 12.1 98.0 (93.6–99.8) 212
FU, follow-up; HM, Home Monitoring; IQR, interquartile range; SD, standard deviation.
Fig. 3. The number of sECG strips for different arrhythmia types suspected by the ICM. Of
note, the SRD criterion is programmed OFF in the standard setting that was used in most
patients. AF, atrial fibrillation; HVR, high ventricular rate; ICM, implantable cardiac
monitor; sECG, subcutaneous ECG; SRD, sudden rate drop.
27P. Søgaard et al. / Journal of Electrocardiology 56 (2019) 24–28sECG, 10.4% of all dayswithmessages) contained themaximumnumber
of six sECG strips (Fig. 2).
The prevalence of different trigger criteria in the transmitted sECG
strips is shown in Fig. 3. The most frequent trigger criteria were AF
(56.8%), bradycardia (29.3%), and HVR (9.1%).
The proportion of patients with at least one sECG attached to a HM
message was 90.1% (191/212). Conversely, no automatically detected
arrhythmia sECG was obtained from 21 patients (9.9%).
Messages with more than one type of suspected arrhythmia
Of the messages with any spontaneously detected sECG, 82.7% re-
ported on only one arrhythmia type. The remaining messages (17.3%)
contained two (15.0%), three (1.8%), or four (0.4%) arrhythmia types.
On the patient level, 117 patients (55.2% of all 212 patients, or 61.3%
of the 191 patients with any spontaneously detected sECG) had at least
one HMmessage with more than one type of arrhythmia.
Discussion
Our analysis of the ICM data transmitted by remote monitoring in
post-MI patients, comprising N200 patients and 230 patient-years of
follow-up, confirms that the physician can rely on remote monitoring
to be informed of all possible significant arrhythmias.
Themedian individual success of daily transmission of HMmessages
was 98.0%. In practical terms, this means that one half of the patients
had a message lost less than once in seven weeks. This figure is compa-
rable to figures from patients with implantable cardioverter/defibrilla-
tors with the same remote monitoring system, indicating that it is
independent of the device type [10]. The transmission success is stable
in the second and third year after implantation (97.7% and 97.1%, re-
spectively), although this result has to be taken with care because
only few patients were followed for longer than two years. In any
way, the long-term results we can report compare favorably withFig. 2.The number of sECG strips per HomeMonitoringmessage. sECG, subcutaneous ECG.results published for the Medtronic LINQ during the first month after
implantation [11].
Beyond the overall transmission success, a second requirement for
reliable identification of relevant arrhythmias is that they are not
supplanted by irrelevant events, e.g., nightly bradycardia, repeating AF
episodes, or inappropriate detections. In theory, the truly relevant
arrhythmias may be less frequent than known arrhythmias or incorrect
detections. Devices that transmit only one event per day may, thus,
be at a significant risk of failing to transmit relevant events. While
we cannot make any statements on the relevance of the episodes
detected in our data set, we found that 17% of the messages with at
least one ECG contained evidence of more than one arrhythmia
type. In such cases, the ICM normally cannot decide which of the
different arrhythmias is clinically most relevant and of the highest
priority to be documented by ECG transmission. We estimate that
an ICM capable of transmitting only one ECG per day would in
about one half of the messages with multiple arrhythmias fail to
transmit the most relevant episode.
Overall, our results show that the ICM and the remote monitoring
technology used in our study are suited for reliable long-termmonitor-
ing, without regular patient visits to the hospital. Even in the third year
after study enrollment, we did not find a meaningful decrease of the
transmission success. Remote monitoring not only simplifies patient
management but also avoids the risk of memory overflow in the de-
vices. The ability to transmit at least one example of all available event
types per day ensures that at least single examples of all relevant ar-
rhythmia types will be reliably reported.
It should be kept in mind that we enrolled patients without known
arrhythmias. One might assume that patient compliance with remote
monitoring would have been even better if they had a primary arrhyth-
mia indication. These patientsmay better understand the purpose of the
ICM than those in whom an arrhythmia is “merely” considered a risk
factor that may, or may not, lead to therapeutic intervention. Under
these considerations, the transmission result is all the more reassuring.
Our analysis is limited by a few issues. First, we did not adjudicate
the arrhythmias as true or false detections because this would have
been beyond the scope of this article. Second, our population of MI
survivors is not the typical guideline-recommended ICM population.
The rate of detections will be different in patients after stroke or with
unclear syncopal events, not only because of a different true arrhythmia
incidence but also because of the possibility to program the devices
according to the specific indication. These constraints prevent a more
accurate estimation of a “loss rate” of relevant arrhythmias in devices
transmitting only one ECG per day. However, we believe that our
general conclusions also apply to typical ICM patients.
28 P. Søgaard et al. / Journal of Electrocardiology 56 (2019) 24–28Conclusion
Our results show a high success rate of remotemonitoring transmis-
sion during long-term monitoring with the tested devices. We have
found hints that the transmission of only one episode per day may
lead to the loss of clinically relevant information if patients with ICMs
are followed by remote monitoring only.
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